Adma Biologics reported $57.13M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Adma Biologics USD 57.13M 4.47M Mar/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Novavax USD 17.9M 220.94M Dec/2025
Omeros USD -65.12M 21.27M Jun/2024
Takeda JPY 162.72B 215.2B Jun/2026